DE2610886C2 - - Google Patents

Info

Publication number
DE2610886C2
DE2610886C2 DE2610886A DE2610886A DE2610886C2 DE 2610886 C2 DE2610886 C2 DE 2610886C2 DE 2610886 A DE2610886 A DE 2610886A DE 2610886 A DE2610886 A DE 2610886A DE 2610886 C2 DE2610886 C2 DE 2610886C2
Authority
DE
Germany
Prior art keywords
compound
general formula
group
preparation
compounds according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2610886A
Other languages
German (de)
English (en)
Other versions
DE2610886A1 (de
Inventor
Hendricus Bernardus Antonius Utrecht Nl Welle
Volkert Weesp Nl Claassen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duphar International Research BV
Original Assignee
Duphar International Research BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duphar International Research BV filed Critical Duphar International Research BV
Publication of DE2610886A1 publication Critical patent/DE2610886A1/de
Application granted granted Critical
Publication of DE2610886C2 publication Critical patent/DE2610886C2/de
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/50—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals
    • C07C251/58—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C249/00—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C249/04—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes
    • C07C249/08—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes by reaction of hydroxylamines with carbonyl compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE19762610886 1975-03-20 1976-03-16 Verbindungen mit antidepressiver wirkung Granted DE2610886A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL7503310A NL7503310A (nl) 1975-03-20 1975-03-20 Verbindingen met antidepressieve werking.

Publications (2)

Publication Number Publication Date
DE2610886A1 DE2610886A1 (de) 1976-10-07
DE2610886C2 true DE2610886C2 (enExample) 1987-09-24

Family

ID=19823424

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19762610886 Granted DE2610886A1 (de) 1975-03-20 1976-03-16 Verbindungen mit antidepressiver wirkung

Country Status (27)

Country Link
US (1) US4085225A (enExample)
JP (1) JPS6026776B2 (enExample)
AR (2) AR211011A1 (enExample)
AT (1) AT340895B (enExample)
AU (1) AU505358B2 (enExample)
BE (1) BE839744A (enExample)
CA (1) CA1076142A (enExample)
CH (4) CH626057A5 (enExample)
DD (1) DD128332A5 (enExample)
DE (1) DE2610886A1 (enExample)
DK (1) DK144942C (enExample)
ES (1) ES446192A1 (enExample)
FI (1) FI61875C (enExample)
FR (1) FR2304336A1 (enExample)
GB (1) GB1535226A (enExample)
GR (1) GR60052B (enExample)
HU (1) HU171030B (enExample)
IE (1) IE43768B1 (enExample)
IL (1) IL49238A (enExample)
IT (1) IT1063064B (enExample)
MX (1) MX9203723A (enExample)
NL (1) NL7503310A (enExample)
PL (3) PL101951B1 (enExample)
SE (1) SE410312B (enExample)
SU (3) SU635867A3 (enExample)
YU (1) YU39345B (enExample)
ZA (1) ZA761434B (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1110460B (it) * 1977-03-02 1985-12-23 Ciba Geigy Ag Prodotti che favoriscono la crescita delle piante e prodotti che proteggono le piante a base di eteri di ossime e di esteri di ossime loro preparazione e loro impiego
FR2639942B1 (fr) * 1988-12-02 1991-03-29 Sanofi Sa Ethers oximes de propenone, procede pour leur preparation et compositions pharmaceutiques les contenant
US5665756A (en) * 1994-08-03 1997-09-09 Hoechst Marion Roussel, Inc. Aminoalkyloximes useful in the treatment of depression and obsessive compulsive disorders
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
PT759299E (pt) * 1995-08-16 2000-09-29 Lilly Co Eli Potenciacao da resposta de serotonina
IN182588B (enExample) 1998-05-12 1999-05-08 Sun Pharmaceutical Ind Ltd
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
IN186677B (enExample) 1999-11-12 2001-10-20 Sun Pharmaceutical Ind Ltd
US20080021085A1 (en) * 2000-04-13 2008-01-24 Mayo Foundation For Medical Education And Research Method of reducing abeta42 and treating diseases
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
US7256191B2 (en) * 2000-04-24 2007-08-14 Aryx Therapeutics Materials and methods for the treatment of depression
US6469064B2 (en) * 2000-04-24 2002-10-22 Aryx Therapeutics Materials and methods for the treatment of depression
AU2002342045C1 (en) * 2001-10-12 2009-07-30 Azevan Pharmaceuticals, Inc. Beta-lactamyl vasopressin Vla antagonists
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
WO2005065069A2 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
ATE449633T1 (de) 2003-09-12 2009-12-15 Pfizer Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
CA2547283C (en) * 2003-11-26 2010-11-09 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
PT1691811E (pt) 2003-12-11 2014-10-30 Sunovion Pharmaceuticals Inc Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
EP1737473A4 (en) * 2004-04-19 2009-08-26 Noven Therapeutics Llc COMBINATIONS OF LITHIUM AND USES THEREOF
WO2005108683A1 (en) * 2004-04-29 2005-11-17 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
CA2618985A1 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
CN104922117A (zh) 2005-03-22 2015-09-23 阿泽范药品公司 用于治疗月经前病症的β-内酰氨基链烷酸
TW200718692A (en) 2005-04-22 2007-05-16 Wyeth Corp Dihydrobenzofuran derivatives and uses thereof
WO2006116151A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
EP1879875A1 (en) * 2005-04-22 2008-01-23 Wyeth Crystal forms opf {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
JP2008538577A (ja) * 2005-04-22 2008-10-30 ワイス ジヒドロベンゾフラン誘導体およびその使用
WO2007008758A2 (en) 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
CA2615813C (en) * 2005-07-19 2015-12-15 Azevan Pharmaceuticals, Inc. Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
CA2615063A1 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009531435A (ja) * 2006-03-24 2009-09-03 ワイス うつ病の治療用の新規な治療組み合わせ
JP4615470B2 (ja) * 2006-03-29 2011-01-19 卓郎 簑和田 大脳の認知力を用いた疾患治療・予防の方法および医薬
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2046119A2 (en) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Treatment of psychiatric disorders
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
WO2008034032A2 (en) * 2006-09-14 2008-03-20 Azevan Pharmaceuticals, Inc. Beta-lactam cannabinoid receptor modulators
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
CA2675132A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation of neurogenesis with use of modafinil
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
US20100092479A1 (en) * 2008-08-18 2010-04-15 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
ME03452B (me) 2009-10-23 2020-01-20 Janssen Pharmaceutica Nv Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
AU2011272738B2 (en) 2010-07-01 2015-08-20 Azevan Pharmaceuticals, Inc. Methods for treating post traumatic stress disorder
AU2012227936A1 (en) 2011-03-17 2013-10-17 Lupin Limited Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
KR101427221B1 (ko) * 2012-08-29 2014-08-13 주식회사 에스텍파마 플루복사민 자유 염기의 정제방법 및 이를 이용한 고순도 플루복사민 말레이트의 제조방법
EP2981518B1 (en) * 2013-04-03 2021-03-03 ZCL Chemicals Ltd. "an improved process for the preparation of fluvoxamine maleate"
WO2015118365A1 (en) 2014-02-07 2015-08-13 Mta Támogatott Kutatócsoportok Irodája Novel use of sigma-1 receptor agonist compounds
BR112016022575A2 (pt) 2014-03-28 2017-08-15 Azevan Pharmaceuticals Inc Composições e métodos para o tratamento de doenças neurodegenerativas
KR20230116948A (ko) * 2016-03-10 2023-08-04 얀센 파마슈티카 엔.브이. 오렉신-2 수용체 길항제를 사용한 우울증의 치료 방법
MA46898A (fr) 2016-11-24 2019-10-02 Sigmadrugs Kutato Korlatolt Feleloessegue Tarsasag Compositions pour la conservation d'organes
KR102790657B1 (ko) 2017-09-15 2025-04-02 아제반 파마슈티칼스, 인코퍼레이티드 뇌 손상을 치료하기 위한 조성물 및 방법
EP3999058A4 (en) 2019-07-19 2023-05-03 Bioxcel Therapeutics, Inc. TREATMENT SCHEMES FOR NON-SEDATING DEXMEDETOMIDIN
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692835A (en) * 1967-04-05 1972-09-19 Jan Van Dijk Pharmacologically active amino-ethyl oximes

Also Published As

Publication number Publication date
ZA761434B (en) 1977-10-26
FI61875C (fi) 1982-10-11
US4085225A (en) 1978-04-18
JPS51125345A (en) 1976-11-01
YU39345B (en) 1984-10-31
PL100052B1 (pl) 1978-08-31
DK144942B (da) 1982-07-12
AR211011A1 (es) 1977-10-14
SU620206A3 (ru) 1978-08-15
SU645559A3 (ru) 1979-01-30
BE839744A (fr) 1976-09-20
DK144942C (da) 1982-12-06
JPS6026776B2 (ja) 1985-06-25
IL49238A0 (en) 1976-05-31
NL7503310A (nl) 1976-09-22
DD128332A5 (de) 1977-11-09
DK115976A (da) 1976-09-21
IT1063064B (it) 1985-02-11
FI760699A7 (enExample) 1976-09-21
IE43768B1 (en) 1981-05-20
DE2610886A1 (de) 1976-10-07
CH629184A5 (de) 1982-04-15
SE410312B (sv) 1979-10-08
FR2304336B1 (enExample) 1979-09-28
AR211153A1 (es) 1977-10-31
AU505358B2 (en) 1979-11-15
FI61875B (fi) 1982-06-30
PL100614B1 (pl) 1978-10-31
IL49238A (en) 1978-08-31
CH626057A5 (enExample) 1981-10-30
HU171030B (hu) 1977-10-28
PL101951B1 (pl) 1979-02-28
GB1535226A (en) 1978-12-13
ES446192A1 (es) 1977-10-01
CH629477A5 (de) 1982-04-30
AT340895B (de) 1978-01-10
MX9203723A (es) 1992-07-01
IE43768L (en) 1976-09-20
GR60052B (en) 1978-04-04
YU71476A (en) 1982-10-31
ATA195476A (de) 1977-05-15
SU635867A3 (ru) 1978-11-30
FR2304336A1 (fr) 1976-10-15
CA1076142A (en) 1980-04-22
SE7603341L (sv) 1976-09-21
CH629761A5 (de) 1982-05-14
AU1214776A (en) 1977-09-22

Similar Documents

Publication Publication Date Title
DE2610886A1 (de) Verbindungen mit antidepressiver wirkung
DE2434911C2 (de) Phenyläthylamin-Derivate und pharmazeutische Zusammensetzungen
DD141520A5 (de) Verfahren zur herstellung neuer derivate von 4-amino-5-alkylsulfonyl-ortho-anisamiden
DE2634288B2 (enExample)
DE3329628C2 (enExample)
DE3002367A1 (de) 2-substituierte trans-5-aryl-2,3,4,4a,5, 9b-hexahydro-1h-pyrido eckige klammer auf 4,3-b eckige klammer zu indole
DE2851028A1 (de) Neue indolo eckige klammer auf 2.3-a eckige klammer zu chinolizidine, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zubereitung
DE2044172C3 (de) Pyrrolderivate, ein Verfahren zu ihrer Herstellung und Arzneimittel
EP0002672B1 (de) Substituierte Pyrrolidine, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel
DE3320394A1 (de) Optisch aktive n-arylierte oxazolidinon-(2)-derivate, deren verwendung als spezifische und reversible inhibitoren von monoaminooxydase des b-typs sowie verfahren zu deren herstellung
EP0096279B1 (de) N-(2-Methoxyethyl)-noroxymorphon, dessen Säureadditionssalze, diese enthaltende Arzneimittel und Verfahren zu deren Herstellung
DE2609437C2 (enExample)
DE2611118C2 (enExample)
DE2609862C2 (enExample)
DE1915230B2 (de) Hydroxyphenylalkylaminderivate, verfahren zu deren herstellung und arzneimittel auf deren basis
DE2610679C2 (de) Sulfinylgruppenhaltige Oximätherderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Mittel
CH670638A5 (enExample)
DE2610302A1 (de) Antidepressive verbindungen
DE2615129A1 (de) Tripeptide, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
DE2421549A1 (de) Naphthalinderivate, verfahren zu ihrer herstellung und arzneimittel
AT282593B (de) Verfahren zur herstellung von neuem racemischem oder optisch aktivem (1-2&#39;-nitrilophenoxy)-2-hydroxy-3-isopropylaminopropan und dessen salzen
AT262289B (de) Verfahren zur Herstellung von neuen Acridanderivaten und ihren Additionssalzen mit anorganischen und organischen Säuren
EP0413302A1 (de) Neue 1,3-Oxazine
DE1518334A1 (de) Neu substituierte Benzylamine und ihre Salze sowie Verfahren zu ihrer Herstellung
DE1951614B2 (de) Substituierte Benzylalkohol, deren physiologisch verträgliche Salze, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel

Legal Events

Date Code Title Description
8128 New person/name/address of the agent

Representative=s name: LEDERER, F., DIPL.-CHEM. DR. MEYER-ROXLAU, R., DIP

8110 Request for examination paragraph 44
8128 New person/name/address of the agent

Representative=s name: LEDERER, F., DIPL.-CHEM. DR., PAT.-ANW., 8000 MUEN

D2 Grant after examination
8364 No opposition during term of opposition